MZ1 co-operates with trastuzumab in HER2 positive breast cancer.

María Del Mar Noblejas-LópezCristina Nieto-JiménezEva M Galán-MoyaDavid Tebar-GarcíaJuan Carlos MonteroAtanasio PandiellaMiguel BurgosAlberto Ocaña

Published in: Journal of experimental & clinical cancer research : CR (2021)

We describe an active novel combination that includes the BET-PROTAC MZ1 and trastuzumab, in HER2+ tumors. Further studies should be performed to confirm these findings and pave the way for their future clinical development.

Keyphrases

positive breast cancer
epidermal growth factor receptor
metastatic breast cancer
current status
tyrosine kinase
case control